Research programme: Alzheimer's disease therapeutics - Afecta PharmaceuticalsAlternative Names: AFX-929
Latest Information Update: 24 Jun 2008
At a glance
- Originator Afecta Pharmaceuticals
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Phase Unknown Alzheimer's disease
Most Recent Events
- 24 Jun 2008 Investigation in Alzheimer's disease in USA (unspecified route)